DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

LLY·Eli Lilly and Company

$.
+. (+.%)
High
$1,085.00
Open
$1,075.00
Market Cap
1002.95B
52W High
$1,133.95
Low
$1,064.08
P. Close
$1,065.00
P/E
39.68
52W Low
$623.78
Fwd P/E
23.97
Mean Target
-
Technical Score (1D)
73
BUY
News Sentiment
84
BULLISH
Eli Lilly is nearing all-time highs, driven by recent positive Phase 1b trial data for Verve-102, a gene-editing therapy designed to permanently lower LDL cholesterol with a single infusion. This development, showing up to 62% LDL-C reduction sustained for up to 18 months, positions Verve-102 as a potential one-time treatment for hypercholesterolemia, with a Phase 2 study now planned. Concurrently, the company's existing GLP-1 drugs, Mounjaro and Zepbound, continue to be highlighted by analysts like Morgan Stanley as crucial drivers of growth, underscoring their market leadership in the obesity space. Further reinforcing Lilly's strength in obesity treatment, recent late-stage data for retatrutide demonstrated strong efficacy, with the highest doses achieving approximately 28-30% weight loss over extended periods. This data aligns with analyst expectations and supports the company's strategic positioning for patients with higher BMIs, ahead of further details expected at the American Diabetes Association meeting. Lilly is actively expanding its weight loss drug portfolio to solidify its position in this rapidly growing market, projected to reach $100 billion, amidst increasing competition. Investors are watching for continued updates on these pipeline advancements and the sustained performance of its current blockbuster drugs.
Earnings Summary
Eli Lilly and Company is a global pharmaceutical firm specializing in the discovery, development, and commercialization of human medicines, with a core business focused on treatments for diabetes, oncology, and immunological disorders. Operating within the Drug Manufacturers - General industry in the Healthcare sector, Lilly's strategic collaborations and diverse therapeutic focus drive its innovation pipeline. The company's recent performance shows a pattern of strong earnings beats, with Q4 2025 EPS of $7.54 exceeding estimates of $6.74, and Q1 2026 EPS of $8.55 surpassing estimates of $6.79. Revenue also demonstrated robust growth, with Q4 2025 revenue at $19.29 billion beating estimates of $18.14 billion, and Q1 2026 revenue at $19.80 billion exceeding estimates of $17.81 billion. This follows a trend of accelerating EPS growth, as Q2 2025 EPS of $6.31 beat estimates of $5.59, and Q3 2025 EPS of $7.02 beat estimates of $5.89. Historically, Eli Lilly has exhibited a strong year-over-year growth trajectory, consistently beating analyst estimates for both EPS and revenue in recent quarters, indicating a sustained positive performance trend. Recent news highlights significant advancements in the weight-loss drug sector, with the experimental drug retatrutide showing remarkable efficacy in late-stage trials, achieving up to 28.3% body weight reduction. This, along with positive developments for its GLP-1 pill Foundayo and potential cancer benefits, positions Lilly strongly in high-growth therapeutic areas. Institutional investors have also shown continued confidence, increasing their stakes. Investors will be watching for further clinical data on retatrutide and Foundayo, as well as any emerging research on potential broader therapeutic applications, to gauge future market implications and sustained growth.

EPS

EstBeatMiss
$2.52$4.30$6.07$7.85$9.62Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$8.81 - -
Q1'26$6.79$8.55+25.9%
Q4'25$6.74$7.54+11.9%
Q3'25$5.89$7.02+19.2%
Q2'25$5.59$6.31+12.9%
Q1'25$3.54$3.34-5.7%

Revenue

EstBeatMiss
$11.6B$14.1B$16.6B$19.2B$21.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$20.5B - -
Q1'26$17.8B$19.8B+11.1%
Q4'25$18.1B$19.3B+6.4%
Q3'25 - $17.6B -
Q2'25 - $15.6B -
Q1'25 - $12.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

LLY Stock Snapshot

LLY is currently trading at $1071.56, giving Eli Lilly and Company a market cap of 1002.95B and a P/E ratio of 39.7. Today's range spans $1064.08–$1085.00, with shares opening at $1075.00 and moving up $6.56 (0.6%) from the prior close. DailyIQ's technical score sits at 73/100 (BUY) with a news sentiment reading of 84/100.

Over the past year LLY has traded between $623.78 and $1133.95 - the current price is +71.8% off the 52-week low and -5.5% from the high.

At 1002.95B in market capitalization, LLY isn't just a stock - it's a macro proxy for the Healthcare sector. The current daily signal is BUY (73/100), the stock is at $1071.56 (in the upper portion of its 52-week range), and sentiment at 84/100 is bullish. bullish momentum at this cap tier tends to be self-reinforcing: ETF inflows, passive rebalancing, and index-tracking strategies all pile in as price action improves. (P/E: 39.7) The 52-week range of $623.78–$1133.95 is the map - the current setup puts buyers in control of the territory that matters.

For portfolio managers constructing Healthcare exposure, a mega-cap with a BUY signal and bullish news backdrop represents the kind of conviction-generating setup that justifies moving from benchmark weight to overweight. The 73/100 technical score at $1071.56 (in the upper portion of its 52-week range) provides the entry discipline; the 1002.95B market cap provides the exit liquidity — a combination most position-sizing frameworks actively seek.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…